0.68 - 0.75
0.33 - 0.86
18.36M / 4.66M (Avg.)
34.50 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
26.24%
Revenue growth above 1.5x 3606.HK's 12.63%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
9.27%
Gross profit growth 1.25-1.5x 3606.HK's 8.02%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
-4.45%
Negative EBIT growth while 3606.HK is at 44.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-4.45%
Negative operating income growth while 3606.HK is at 49.39%. Joel Greenblatt would press for urgent turnaround measures.
23.51%
Net income growth under 50% of 3606.HK's 49.85%. Michael Burry would suspect the firm is falling well behind a key competitor.
21.43%
EPS growth under 50% of 3606.HK's 47.83%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
21.43%
Diluted EPS growth under 50% of 3606.HK's 47.83%. Michael Burry would worry about an eroding competitive position or excessive dilution.
1.69%
Slight or no buybacks while 3606.HK is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
1.59%
Diluted share change of 1.59% while 3606.HK is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
19.78%
OCF growth under 50% of 3606.HK's 49.59%. Michael Burry might suspect questionable revenue recognition or rising costs.
25.16%
FCF growth under 50% of 3606.HK's 70.11%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
21014.84%
10Y revenue/share CAGR above 1.5x 3606.HK's 232.38%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
24.65%
5Y revenue/share CAGR at 75-90% of 3606.HK's 31.47%. Bill Ackman would encourage strategies to match competitor’s pace.
-3.39%
Negative 3Y CAGR while 3606.HK stands at 7.41%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-9466.85%
Negative 10Y OCF/share CAGR while 3606.HK stands at 381.45%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-5313.50%
Negative 5Y OCF/share CAGR while 3606.HK is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1349.92%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
23.83%
Below 50% of 3606.HK's 255.95%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-22.39%
Negative 5Y net income/share CAGR while 3606.HK is 75.56%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
13.82%
Below 50% of 3606.HK's 52.65%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
95.36%
5Y equity/share CAGR at 50-75% of 3606.HK's 131.72%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
40.98%
Below 50% of 3606.HK's 86.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
93.73%
5Y dividend/share CAGR above 1.5x 3606.HK's 1.09%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
84.64%
3Y dividend/share CAGR above 1.5x 3606.HK's 9.35%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
47.11%
AR growth well above 3606.HK's 8.69%. Michael Burry fears inflated revenue or higher default risk in the near future.
-21.61%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
22.34%
Asset growth above 1.5x 3606.HK's 6.22%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.73%
Positive BV/share change while 3606.HK is negative. John Neff sees a clear edge over a competitor losing equity.
1816.96%
Debt growth far above 3606.HK's 29.30%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
80.16%
R&D growth of 80.16% while 3606.HK is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
47.97%
We expand SG&A while 3606.HK cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.